Undefined Antigen Based Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for undefined antigen-based vaccines. We guarantee the finest results for our customers all over the world.

A rationale for using undefined antigen vaccines to treat patients with cancer is that for the most common types of malignancy, e.g. carcinomas of epithelial origin, tumor antigens have not been well-characterized. Furthermore, in contrast to defined antigen vaccines, vaccines using intact tumor cells, or preparations derived from whole tumor cells, contain not only shared tumor antigens, but also many TSA, to which the host may not have developed tolerance.

Creative Biolabs provides development strategies that use undefined or ill-defined antigen preparations derived from whole tumor cells as the cancer vaccines, including whole tumor cells (both autologous and allogeneic), gene-modified cells (genes encoding cytokines, chemokines, and costimulatory molecules), cell-derived materials (lysates, apoptotic bodies, exosomes, heat shock proteins), and tumor-APC fusion cells.

Whole Tumor Cells

Early versions of whole cell vaccines usually consisted of killed tumor cells or tumor cell lysates mixed with bacterial adjuvants such as Bacillus Calmette Guerin (BCG) and Corynebacterium parvum. Although the mechanisms of the bacterial adjuvants are still not understood very well, the innate immune responses to various bacterial components play a critical role in bridging the innate immune response and adaptive immunity to tumor antigens. In contrast to the crude bacterial adjuvants used for the generation of early cancer vaccines, more recent generations of whole cell tumor vaccines have comprised genetically modified tumor cells using defined immunemodulating genes, including cytokines, chemokines, and costimulatory molecules.

Cell-Derived Materials

• Lysates. Tumor cell-derived materials, including lysates (freeze-thaw, sonication and oncolysate [lysis by lytic viruses]), shed antigens, apoptotic bodies, exosomes, and enriched or purified heat shock proteins have been pursued as alternatives to whole cell vaccines. These materials should contain most of the antigens from tumor cells;
• Heat Shock Proteins (HSPs). HSPs purified from one tumor cell line are able to elicit antitumor responses that are specific for that tumor cell line only and HSPs from normal tissues fail to induce immune responses to any tumor cells;
• Exosomes. Exosomes are small membrane vesicles secreted by many different cell types as a consequence of fusion of multivesicular late endosomes/lysosomes with the plasma membrane. Tumor-derived exosomes contain a rich source of antigens and HSP that can be transferred to DCs for cross-priming of T cells.

Dendritic Cells

Dendritic cells initiate the T-cell response to many different antigens, including tumor antigens. Because of their unique ability to activate native T cells, DC have been evaluated by many investigators.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.